Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Breast Cancer
; 29(1): 186-188, 2022 Jan.
Article
em En
| MEDLINE
| ID: mdl-34562260
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article